|
| Press Releases |
|
 |
|
| Tuesday, August 26, 2025 |
|
|
Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation |
| Essex Bio-Technology Limited ('Essex' and its subsidiary the 'Group', Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor ('rb-bFGF'), today announced its interim results for the six months ended 30 June 2025 ('the period under review'). more info >> |
|
| Wednesday, August 13, 2025 |
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration |
| Essex Bio-Technology Limited ('Essex' or the 'Group', Stock Code: 1061.HK) is pleased to announce that a Biologics License Application ('BLA') for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation ('CDE') of the National Medical Products Administration ('NMPA') in China. The product is jointly developed by the Group and Shanghai Henlius Biotech, Inc. ('Henlius', Stock Code: 2696.HK) for the treatment of wet age-related macular degeneration ('wet-AMD') in China. more info >> |
|
| Friday, July 25, 2025 |
|
|
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China |
| Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that(Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC. more info >> |
|
| Monday, March 18, 2024 |
|
|
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1% |
| Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2023. more info >> |
|
| Wednesday, August 16, 2023 |
|
|
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22% |
Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").
more info >> |
|
| Wednesday, July 26, 2023 |
|
|
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc. more info >> |
|
| Friday, April 14, 2023 |
|
|
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore |
| Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. ("Majeton"), has entered into an exclusive Distribution Agreement with Osteopore Limited ("Osteopore") to promote and sell Osteopore's dental and oral maxillofacial products ("Products") in Singapore. more info >> |
|
| Tuesday, April 11, 2023 |
|
|
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China |
| Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement ("Agency Agreement") with Gunze Medical Devices (Shenzhen) Ltd. more info >> |
|
| Wednesday, March 8, 2023 |
|
|
Essex Bio-Technology Announces 2022 Annual Financial Results |
Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022.
more info >> |
|
| Wednesday, February 22, 2023 |
|
|
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited ("Essex Bio-Investment") and Zhuhai Essex Bio-Pharmaceutical Co. Ltd ("Zhuhai Essex") more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 29, 2025 0:53 JST
|
|
|
Mazda Presents World Premiere of Two Vision Models at Japan Mobility Show 2025
Oct 29, 2025 0:33 JST
|
|
|
Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025
Oct 29, 2025 0:26 JST
|
|
|
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
Oct 29, 2025 0:18 JST
|
|
|
Overview of Honda CEO Speech at the Japan Mobility Show 2025
Oct 29, 2025 0:00 JST
|
|
|
Honda Presents World Premiere of the Prototype of Honda 0 a, new SUV Model for Honda 0 Series at Japan Mobility Show 2025
Oct 29, 2025 23:55 JST
|
|
|
Honda Presents World Premiere of Super-ONE Prototype Compact EV at Japan Mobility Show 2025
Oct 29, 2025 23:50 JST
|
|
|
Mitsubishi Motors Debuts Mitsubishi Elevance Concept and Adventure-Inspiring Lineup at Japan Mobility Show 2025
Oct 29, 2025 23:39 JST
|
|
|
Fujitsu and PwC Japan partner on economic security measures for sovereign cloud solution
Oct 29, 2025 23:22 JST
|
|
|
Hitachi Rail becomes world's first transportation firm to adopt new NVIDIA IGX Thor solution for real-time AI
Oct 29, 2025 23:00 JST
|
|
|
Ecological Threat Report 2025: Extreme Wet-Dry Seasons Emerge as Critical Conflict Catalyst
Oct 29, 2025 13:00 HKT/SGT
|
|
|
Reclaims Global Positions for Next Phase of Growth with Successful Placement and Strong Sector Momentum
Oct 29, 2025 11:14 HKT/SGT
|
|
|
GTJAI Assisted Deepexi Technology in Successfully Listing on the Main Board of the Hong Kong Stock Exchange
Oct 29, 2025 10:30 HKT/SGT
|
|
|
GTJAI Serves as the Sole Sponsor for CIG, Achieving the Largest IPO in the Telecommunications Equipment Sector across Both A-shares and H-shares Markets
Oct 29, 2025 10:27 HKT/SGT
|
|
|
Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center 
Oct 29, 2025 11:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
